Literature DB >> 28569090

Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain.

Suresh Kumar Swaminathan1,2, Kristen M Ahlschwede1,3, Vidur Sarma1,2, Geoffry L Curran2,3, Rajesh S Omtri1, Teresa Decklever2, Val J Lowe2, Joseph F Poduslo3, Karunya K Kandimalla1,3.   

Abstract

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood-brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer's disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.

Entities:  

Keywords:  Alzheimer's disease; SPECT; blood–brain barrier; cerebrovascular disease; diabetes; endothelium; insulin; pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28569090      PMCID: PMC5987944          DOI: 10.1177/0271678X17709709

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  46 in total

Review 1.  The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

Authors:  R Deane; A Sagare; B V Zlokovic
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

2.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

3.  Kinetic evidence that Glut4 follows different endocytic pathways than the receptors for transferrin and alpha2-macroglobulin.

Authors:  Estifanos N Habtemichael; Paul Duffield Brewer; Irina Romenskaia; Cynthia Corley Mastick
Journal:  J Biol Chem       Date:  2011-01-20       Impact factor: 5.157

4.  GLUT4 is internalized by a cholesterol-dependent nystatin-sensitive mechanism inhibited by insulin.

Authors:  Vincent Blot; Timothy E McGraw
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

Review 5.  Alzheimer disease as a vascular disorder: nosological evidence.

Authors:  J C de la Torre
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

Review 6.  Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes.

Authors:  Robert T Watson; Makoto Kanzaki; Jeffrey E Pessin
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

7.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

Authors:  Rashid Deane; Zhenhua Wu; Abhay Sagare; Judianne Davis; Shi Du Yan; Katie Hamm; Feng Xu; Margaret Parisi; Barbra LaRue; Hong Wei Hu; Patricia Spijkers; Huang Guo; Xiaomei Song; Peter J Lenting; William E Van Nostrand; Berislav V Zlokovic
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

Review 8.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

9.  Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease.

Authors:  E Hellström-Lindahl; M Viitanen; A Marutle
Journal:  Neurochem Int       Date:  2009-03-20       Impact factor: 3.921

10.  Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study.

Authors:  L W de Jong; K van der Hiele; I M Veer; J J Houwing; R G J Westendorp; E L E M Bollen; P W de Bruin; H A M Middelkoop; M A van Buchem; J van der Grond
Journal:  Brain       Date:  2008-11-20       Impact factor: 13.501

View more
  12 in total

Review 1.  Routes for the delivery of insulin to the central nervous system: A comparative review.

Authors:  Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Neurol       Date:  2018-11-27       Impact factor: 5.330

2.  Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis.

Authors:  Andrew L Zhou; Suresh K Swaminathan; Geoffry L Curran; Joseph F Poduslo; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

3.  Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults.

Authors:  Xiaobo Peng; Zihui Xu; Xiaoxing Mo; Qianqian Guo; Jiawei Yin; Mengdai Xu; Zhao Peng; Taoping Sun; Li Zhou; Xiaolin Peng; Shufang Xu; Wei Yang; Wei Bao; Zhilei Shan; Xiaoqin Li; Liegang Liu
Journal:  Diabetologia       Date:  2020-02-07       Impact factor: 10.122

Review 4.  Breakdown of the blood-brain barrier: A mediator of increased Alzheimer's risk in patients with metabolic disorders?

Authors:  Corey J Frank; Ewan C McNay
Journal:  J Neuroendocrinol       Date:  2021-12-13       Impact factor: 3.627

5.  Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium.

Authors:  Zengtao Wang; Nidhi Sharda; Geoffry L Curran; Ling Li; Val J Lowe; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2021-10-19       Impact factor: 5.364

6.  High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-β Distribution between Brain and Plasma.

Authors:  Suresh K Swaminathan; Andrew L Zhou; Kristen M Ahlschwede; Geoffry L Curran; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2020-08-10       Impact factor: 4.030

Review 7.  Targeting Insulin Resistance to Treat Cognitive Dysfunction.

Authors:  Anit Tyagi; Subbiah Pugazhenthi
Journal:  Mol Neurobiol       Date:  2021-01-23       Impact factor: 5.682

8.  Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-β in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice.

Authors:  Chaitanya Chakravarthi Gali; Elham Fanaee-Danesh; Martina Zandl-Lang; Nicole Maria Albrecher; Carmen Tam-Amersdorfer; Anika Stracke; Vinay Sachdev; Florian Reichmann; Yidan Sun; Afrim Avdili; Marielies Reiter; Dagmar Kratky; Peter Holzer; Achim Lass; Karunya K Kandimalla; Ute Panzenboeck
Journal:  Mol Cell Neurosci       Date:  2019-07-02       Impact factor: 4.314

9.  Changes of blood-brain-barrier function and transfer of amyloid beta in rats with collagen-induced arthritis.

Authors:  Po-Hsuan Lai; Ting-Hsuan Wang; Nai-You Zhang; Kuo-Chen Wu; Chung-Chen Jane Yao; Chun-Jung Lin
Journal:  J Neuroinflammation       Date:  2021-01-30       Impact factor: 8.322

Review 10.  Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease.

Authors:  Dong Wang; Fanglian Chen; Zhaoli Han; Zhenyu Yin; Xintong Ge; Ping Lei
Journal:  Front Cell Neurosci       Date:  2021-07-19       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.